Cantor Fitzgerald analyst Ross Osborn downgraded Pacific Biosciences to Neutral from Overweight with an unchanged price target of $12, citing valuation. Pacific Biosciences launched a new long read and short read sequencing system in October and the stock has rallied 33%, but Osborn believes the new offerings are now baked into the company’s valuation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PACB:
- Pacific Biosciences partners with University of Tokyo
- PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022
- Pacific Biosciences sees Q4 revenue $27.3M, consensus $27.88M
- Pacific Biosciences initiated with an Outperform at Scotiabank
- Pac Bio call volume above normal and directionally bullish